Bio-Techne Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
(Address of Principal Executive Offices) (Zip Code) |
|
( |
(Registrant’s Telephone Number, Including Area Code) |
|
Not Applicable |
(Former Name or Former Address, if Changed Since Last Report) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
A copy of the press release issued by Bio-Techne Corporation (the “Company”) on October 30, 2024, describing the results of operations for the quarter ended September 30, 2024 and its financial condition as of September 30, 2024 is attached hereto as Exhibit 99.1.
The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 5.07 Submission of Matters to a Vote of Security Holders
A quorum was present at the Annual Meeting with 148,168,864 shares represented personally or by proxy, which represents approximately 93.39% of the outstanding shares of the Company's common stock. The voting results at the Annual Meeting were as set forth below.
Proposal No. 1 – The shareholders voted to set the number of directors at nine:
For | Against | Abstain | Broker Non-Vote |
147,416,243 | 587,153 | 106,653 | 0 |
Proposal No. 2 – The shareholders elected each of the nominees to the Board of Directors:
For | Against | Abstain | Broker Non-Vote | |
Robert V. Baumgartner | 135,629,662 | 7,184,651 | 108,555 | 5,187,181 |
Julie L. Bushman | 137,726,895 | 5,090,472 | 105,501 | 5,187,181 |
John L. Higgins | 135,544,819 | 7,264,115 | 113,934 | 5,187,181 |
Roeland Nusse | 141,573,245 | 1,241,096 | 108,527 | 5,187,181 |
Kim Kelderman | 142,088,978 | 730,531 | 103,359 | 5,187,181 |
Joseph D. Keegan | 139,194,251 | 3,617,533 | 111,084 | 5,187,181 |
Alpna Seth | 137,509,635 | 5,302,948 | 110,285 | 5,187,181 |
Rupert Vessey | 140,985,843 | 1,825,907 | 111,118 | 5,187,181 |
Judith Klimovsky | 142,641,977 | 176,715 | 104,176 | 5,187,181 |
Each nominee was elected by a majority voting standard defined in the Amended and Restated Articles of Incorporation.
Proposal No. 3 – The shareholders adopted a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement:
For | Against | Abstain | Broker Non-Vote |
122,860,464 | 19,912,153 | 150,251 | 5,187,181 |
Proposal No. 4 – The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2025.
For | Against | Abstain | Broker Non-Vote |
34,862,262 | 856,480 | 5,701 | 0 |
Item 8.01 Other Events
A copy of the press release issued by Bio-Techne Corporation on October 30, 2024, announcing a cash dividend is attached hereto as Exhibit 99.2.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits | |
99.1 | Press Release, dated October 30, 2024, announcing results of operations |
|
|
99.2 | Press Release, dated October 30, 2024, announcing cash dividend |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIO-TECHNE CORPORATION | ||
Date: October 30, 2024 | By: | /s/ Shane V. Bohnen |
Shane V. Bohnen | ||
Senior Vice President, General Counsel and Secretary | ||